SCHEMBL20181879

SCHEMBL20181879

C#CC(C)n1cc(C)c2c(N)ncnc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 7/20 0.41
ADK P55263 1/20 0.40
PIK3CD O00329 4/20 0.39
PIK3CA P42336 3/20 0.39
PIK3CB P42338 3/20 0.39
PIK3CG P48736 3/20 0.39
PRKDC P78527 3/20 0.39
PI4KB Q9UBF8 3/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
PI4KA P42356 1/20 0.39
PI4K2B Q8TCG2 1/20 0.39
PI4K2A Q9BTU6 1/20 0.39
KDR P35968 8/20 0.38
SRC P12931 6/20 0.38
LCK P06239 4/20 0.38
TEK Q02763 3/20 0.38
ABL1 P00519 3/20 0.37
LRRK2 Q5S007 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24458478 0.85 RET (0.54) RETADKPIK3CDPIK3CAPIK3CB
SCHEMBL20162723 0.84 DYRK3 (0.44) RETADKPIK3CDPIK3CAPIK3CB
SCHEMBL30038177 0.84 DYRK3 (0.44) RETADKPIK3CDPIK3CAPIK3CB
SCHEMBL2618932 0.83 PIK3CD (0.52) RETADKPIK3CDPIK3CAPIK3CB
SCHEMBL20182341 0.82 ADK (0.40) ADKSRC
SCHEMBL20181884 0.82 ADORA2A (0.39) RETADKPIK3CDPIK3CAPIK3CB
SCHEMBL20182185 0.80 RET (0.41) RETADKPIK3CDPIK3CAPIK3CB
SCHEMBL19775103 0.78 ADORA2A (0.56) RETADKPIK3CDPIK3CAPIK3CB
SCHEMBL30037235 0.77 KDR (0.58) RETPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL20162806 0.77 KDR (0.58) RETPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018094137-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) 2018-05-24 WO disclosed